The latest updates from Eyerising International.
Eyerising International has received regulatory approval in additional markets, bringing the total number of approved countries to over 30 across Europe, Asia, and Oceania.
Read more →Results from our ongoing long-term clinical trials continue to demonstrate sustained efficacy of RLRL therapy in slowing myopia progression over 3 and 5-year follow-up periods.
Read more →Our team presented the latest clinical evidence for RLRL therapy at the Asia-Pacific Academy of Ophthalmology annual congress, generating significant interest from clinicians across the region.
Read more →We are excited to introduce Willow, an interactive companion character designed to help young patients feel engaged and motivated throughout their myopia management journey.
Read more →Eyerising International has partnered with additional leading ophthalmic research institutions to expand our clinical evidence base for RLRL therapy across diverse populations.
Read more →Eyerising International has successfully renewed its ISO 13485:2016 quality management system certification, reaffirming our commitment to the highest standards in medical device manufacturing.
Read more →Subscribe to our newsletter for the latest news, clinical updates, and events.
Contact Us